Skip to main content
Erschienen in: International Journal of Legal Medicine 6/2011

01.11.2011 | Original Article

Deaths involving contraindicated and inappropriate combinations of serotonergic drugs

verfasst von: Jennifer L. Pilgrim, Dimitri Gerostamoulos, Olaf H. Drummer

Erschienen in: International Journal of Legal Medicine | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

In the Australian state of Victoria, all fatalities that were recorded from 2002 through to 2008 involving the use of certain serotonin active drugs (tramadol, venlafaxine, fluoxetine, sertraline, citalopram and paroxetine), were reviewed to assess the incidence of contraindicated or ill advised drug combinations. More than 1,000 were identified of which 326 cases formed the basis of this study. These cases involved contraindicated or inappropriate drug combinations that can lead to adverse drug reactions (ADRs) and subsequent fatal toxicity. Of these, 46% were drug-related, 35% were a result of natural disease and 13% were classified as external injury cases. The remaining cases were those where the cause of death (COD) was unascertained. Tramadol was the most common drug, usually detected alongside a serotonergic antidepressant (in 20% of cases). Twenty-five (8%) cases involved contraindicated drug combinations while the remainder (301 cases, 92%) involved drug combinations that are associated with adverse interactions ranging from minor to major severity. Of these 326 cases, the Coroner determined 166 cases (51%) to be acts of intentional self-harm or drug misuse, with the remainder unascertained or attributed to natural disease. Very few post-mortem reports and Coroners’ findings made mention of possible ADRs when such combinations were actually present. The majority of cases comprising contraindicated drug combinations involved the combined use of five drugs (24%) at the time of death. A combination of three to five drugs was most common in cases involving inadvisable drug combinations. Combined drug toxicity was the most common COD, with heart disease the most common co-morbidity.
Literatur
1.
Zurück zum Zitat Roughead EE, Lexchin J (2006) Adverse drug events: counting is not enough, action is needed. Med J Aust 184(7):315–316PubMed Roughead EE, Lexchin J (2006) Adverse drug events: counting is not enough, action is needed. Med J Aust 184(7):315–316PubMed
2.
Zurück zum Zitat Runciman WB, Roughead EE, Semple SJ, Adams RJ (2003) Adverse drug events and medication errors in Australia. Int J Qual Health Care 15(Suppl 1):i49–i59PubMedCrossRef Runciman WB, Roughead EE, Semple SJ, Adams RJ (2003) Adverse drug events and medication errors in Australia. Int J Qual Health Care 15(Suppl 1):i49–i59PubMedCrossRef
3.
Zurück zum Zitat Bijl D (2004) The serotonin syndrome. Neth J Med 62:309–314PubMed Bijl D (2004) The serotonin syndrome. Neth J Med 62:309–314PubMed
4.
Zurück zum Zitat Birmes P, Coppin D, Schmitt L, Lauque D (2003) Serotonin syndrome: a brief review. CMAJ 168(11):1439–1442PubMed Birmes P, Coppin D, Schmitt L, Lauque D (2003) Serotonin syndrome: a brief review. CMAJ 168(11):1439–1442PubMed
6.
Zurück zum Zitat Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705–713PubMed Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705–713PubMed
9.
Zurück zum Zitat Tamblyn RM, McLeod PJ, Abrahamowicz M, Monette J, Gayton DC, Berkson L, Dauphinee WD, Grad RM, Huang AR, Isaac LM, Schnarch BS, Snell LS (1994) Questionable prescribing for elderly patients in Quebec. CMAJ 150(11):1801–1809PubMed Tamblyn RM, McLeod PJ, Abrahamowicz M, Monette J, Gayton DC, Berkson L, Dauphinee WD, Grad RM, Huang AR, Isaac LM, Schnarch BS, Snell LS (1994) Questionable prescribing for elderly patients in Quebec. CMAJ 150(11):1801–1809PubMed
10.
Zurück zum Zitat Hamilton H, Gallagher P, O’Mahony D (2009) Inappropriate prescribing and adverse drug events in older people. BMC Geriatr 9(1):5PubMedCrossRef Hamilton H, Gallagher P, O’Mahony D (2009) Inappropriate prescribing and adverse drug events in older people. BMC Geriatr 9(1):5PubMedCrossRef
11.
Zurück zum Zitat Jones JK, Fife D, Curkendall S, Goehring E Jr, Guo JJ, Shannon M (2001) Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 286(13):1607–1609PubMedCrossRef Jones JK, Fife D, Curkendall S, Goehring E Jr, Guo JJ, Shannon M (2001) Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 286(13):1607–1609PubMedCrossRef
12.
Zurück zum Zitat Stang P, Morris L, Kempf J, Henderson S, Yood MU, Oliveria S (2007) The coprescription of contraindicated drugs with statins: continuing potential for increased risk of adverse events. Am J Ther 14(1):30–40PubMedCrossRef Stang P, Morris L, Kempf J, Henderson S, Yood MU, Oliveria S (2007) The coprescription of contraindicated drugs with statins: continuing potential for increased risk of adverse events. Am J Ther 14(1):30–40PubMedCrossRef
13.
Zurück zum Zitat Roughead EE, Anderson B, Gilbert AL (2007) Potentially inappropriate prescribing among Australian veterans and war widows/widowers. Intern Med J 37(6):402–405PubMedCrossRef Roughead EE, Anderson B, Gilbert AL (2007) Potentially inappropriate prescribing among Australian veterans and war widows/widowers. Intern Med J 37(6):402–405PubMedCrossRef
14.
Zurück zum Zitat Ringland C, Mant A, McGettigan P, Mitchell P, Kelman C, Buckley N, Pearson SA (2008) Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data. Br J Clin Pharmacol 66(5):682–688PubMed Ringland C, Mant A, McGettigan P, Mitchell P, Kelman C, Buckley N, Pearson SA (2008) Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data. Br J Clin Pharmacol 66(5):682–688PubMed
15.
Zurück zum Zitat Pilgrim JL, Gerostamoulos D, Drummer OH (2010) Deaths involving serotonergic drugs. Forensic Sci Int 198(1–3):110–117PubMedCrossRef Pilgrim JL, Gerostamoulos D, Drummer OH (2010) Deaths involving serotonergic drugs. Forensic Sci Int 198(1–3):110–117PubMedCrossRef
16.
Zurück zum Zitat Gillman PK (2005) Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 95(4):434–441PubMedCrossRef Gillman PK (2005) Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 95(4):434–441PubMedCrossRef
17.
Zurück zum Zitat Houlihan DJ (2004) Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. Ann Pharmacother 38(3):411–413PubMedCrossRef Houlihan DJ (2004) Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. Ann Pharmacother 38(3):411–413PubMedCrossRef
18.
Zurück zum Zitat Hernandez JL, Ramos FJ, Infante J, Rebollo M, Gonzalez-Macias J (2002) Severe serotonin syndrome induced by mirtazapine monotherapy. Ann Pharmacother 36(4):641–643PubMedCrossRef Hernandez JL, Ramos FJ, Infante J, Rebollo M, Gonzalez-Macias J (2002) Severe serotonin syndrome induced by mirtazapine monotherapy. Ann Pharmacother 36(4):641–643PubMedCrossRef
19.
Zurück zum Zitat Gillman PK (2006) A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 59(11):1046–1051PubMedCrossRef Gillman PK (2006) A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 59(11):1046–1051PubMedCrossRef
20.
Zurück zum Zitat Rahola JG (2001) Antidepressants: pharmacological profile and clinical consequences. Int J Psychiatry Clin Pract 5(1):19–28 Rahola JG (2001) Antidepressants: pharmacological profile and clinical consequences. Int J Psychiatry Clin Pract 5(1):19–28
21.
Zurück zum Zitat Eap CB, Bertschy G, Powell K, Baumann P (1997) Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol 17(2):113–117PubMedCrossRef Eap CB, Bertschy G, Powell K, Baumann P (1997) Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol 17(2):113–117PubMedCrossRef
22.
Zurück zum Zitat Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, Kosel M, Baumann P, Eap CB (2002) Paroxetine increases steady-state concentrations of (r)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 22(2):211–215PubMedCrossRef Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, Kosel M, Baumann P, Eap CB (2002) Paroxetine increases steady-state concentrations of (r)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 22(2):211–215PubMedCrossRef
23.
Zurück zum Zitat Drummer OH (2004) Postmortem toxicology of drugs of abuse. Forensic Sci Int 142(2–3):101–113PubMedCrossRef Drummer OH (2004) Postmortem toxicology of drugs of abuse. Forensic Sci Int 142(2–3):101–113PubMedCrossRef
25.
Zurück zum Zitat Buajordet I, Ebbesen J, Erikssen J, Brors O, Hilberg T (2001) Fatal adverse drug events: the paradox of drug treatment. J Intern Med 250(4):327–341PubMedCrossRef Buajordet I, Ebbesen J, Erikssen J, Brors O, Hilberg T (2001) Fatal adverse drug events: the paradox of drug treatment. J Intern Med 250(4):327–341PubMedCrossRef
26.
Zurück zum Zitat Shah S, Aslam M, Avery A (2001) A survey of prescription errors in general practice. Pharm J 267:860–863 Shah S, Aslam M, Avery A (2001) A survey of prescription errors in general practice. Pharm J 267:860–863
27.
Zurück zum Zitat Gleason OC, Yates WR, Philipsen MA, Isbell MD, Pollock BG (2004) Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics 45(1):29–33PubMedCrossRef Gleason OC, Yates WR, Philipsen MA, Isbell MD, Pollock BG (2004) Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics 45(1):29–33PubMedCrossRef
28.
Zurück zum Zitat Henz S, Maeder MT, Huber S, Schmid M, Loher M, Fehr T (2008) Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions. Nephrol Dial Transplant 23(12):3939–3945PubMedCrossRef Henz S, Maeder MT, Huber S, Schmid M, Loher M, Fehr T (2008) Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions. Nephrol Dial Transplant 23(12):3939–3945PubMedCrossRef
29.
Zurück zum Zitat Zhang M, Holman CD, Price SD, Sanfilippo FM, Preen DB, Bulsara MK (2009) Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ 338:a2752PubMedCrossRef Zhang M, Holman CD, Price SD, Sanfilippo FM, Preen DB, Bulsara MK (2009) Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ 338:a2752PubMedCrossRef
30.
Zurück zum Zitat Mangoni A, Jackson S (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14PubMedCrossRef Mangoni A, Jackson S (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14PubMedCrossRef
31.
Zurück zum Zitat Spinewine A, Schmader K, Barber N, Hughes C, Lapane K, Swine C, Hanlon J (2007) Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 370:173–184PubMedCrossRef Spinewine A, Schmader K, Barber N, Hughes C, Lapane K, Swine C, Hanlon J (2007) Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 370:173–184PubMedCrossRef
33.
Zurück zum Zitat Australian Bureau of Statistics (2003) Drug-induced death, Australia, 1991–2001. Canberra, Australia Australian Bureau of Statistics (2003) Drug-induced death, Australia, 1991–2001. Canberra, Australia
34.
Zurück zum Zitat Butzbach DM (2009) The influence of putrefaction and sample storage on post-mortem toxicology results. Forensic Sci Med Pathol 6(1):35–45PubMedCrossRef Butzbach DM (2009) The influence of putrefaction and sample storage on post-mortem toxicology results. Forensic Sci Med Pathol 6(1):35–45PubMedCrossRef
35.
Zurück zum Zitat Barnhart FE, Bonnell HJ, Rossum KM (2001) Post-mortem drug redistribution. Forensic Sci Rev 13(2):101–129 Barnhart FE, Bonnell HJ, Rossum KM (2001) Post-mortem drug redistribution. Forensic Sci Rev 13(2):101–129
36.
Zurück zum Zitat Clarot F, Goulle JP, Vaz E, Proust B (2003) Fatal overdoses of tramadol: is benzodiazepine a risk factor of lethality? Forensic Sci Int 134(1):57–61PubMedCrossRef Clarot F, Goulle JP, Vaz E, Proust B (2003) Fatal overdoses of tramadol: is benzodiazepine a risk factor of lethality? Forensic Sci Int 134(1):57–61PubMedCrossRef
37.
Zurück zum Zitat Goldberg RM, Mabee J, Chan L, Wong S (1996) Drug–drug and drug–disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 14(5):447–450PubMedCrossRef Goldberg RM, Mabee J, Chan L, Wong S (1996) Drug–drug and drug–disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 14(5):447–450PubMedCrossRef
38.
Zurück zum Zitat Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB (2005) Interaction of serotonergic antidepressants and opioid analgesics: is serotonin syndrome going undetected? J Am Med Dir Assoc 6(4):265–269PubMedCrossRef Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB (2005) Interaction of serotonergic antidepressants and opioid analgesics: is serotonin syndrome going undetected? J Am Med Dir Assoc 6(4):265–269PubMedCrossRef
39.
Zurück zum Zitat Mahlberg R, Kunz D, Sasse J, Kirchheiner J (2004) Serotonin syndrome with tramadol and citalopram. Am J Psychiatry 161(6):1129PubMedCrossRef Mahlberg R, Kunz D, Sasse J, Kirchheiner J (2004) Serotonin syndrome with tramadol and citalopram. Am J Psychiatry 161(6):1129PubMedCrossRef
40.
Zurück zum Zitat Launiainen T, Rasanen I, Vuori E, Ojanpera I (2010) Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int J Legal Med. doi:10.1007/s00414-010-0461-5 Launiainen T, Rasanen I, Vuori E, Ojanpera I (2010) Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int J Legal Med. doi:10.​1007/​s00414-010-0461-5
41.
Zurück zum Zitat Dams R, Benijts TH, Lambert WE, Van Bocxlaer JF, Van Varenbergh D, Van Peteghem C, De Leenheer AP (2001) A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. J Anal Toxicol 25(2):147–151PubMed Dams R, Benijts TH, Lambert WE, Van Bocxlaer JF, Van Varenbergh D, Van Peteghem C, De Leenheer AP (2001) A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. J Anal Toxicol 25(2):147–151PubMed
42.
Zurück zum Zitat Marino MR, Langenbacher M, Ulderman HD (1996) Interaction of nefazodone and fluoxetine. Clin Pharmacol Ther 59:180CrossRef Marino MR, Langenbacher M, Ulderman HD (1996) Interaction of nefazodone and fluoxetine. Clin Pharmacol Ther 59:180CrossRef
43.
Zurück zum Zitat Martinelli V, Bocchetta A, Palmas AM, Del Zompo M (1993) An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol 36(6):615–616PubMed Martinelli V, Bocchetta A, Palmas AM, Del Zompo M (1993) An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol 36(6):615–616PubMed
44.
Zurück zum Zitat Bertschy G, Vandel S, Vandel B, Allers G, Volmat R (1991) Fluvoxamine-tricyclic antidepressant interaction. An accidental finding. Eur J Clin Pharmacol 40(1):119–120PubMedCrossRef Bertschy G, Vandel S, Vandel B, Allers G, Volmat R (1991) Fluvoxamine-tricyclic antidepressant interaction. An accidental finding. Eur J Clin Pharmacol 40(1):119–120PubMedCrossRef
45.
Zurück zum Zitat Weschules DJ, Bain KT, Richeimer S (2008) Actual and potential drug interactions associated with methadone. Pain Med 9(3):315–344PubMedCrossRef Weschules DJ, Bain KT, Richeimer S (2008) Actual and potential drug interactions associated with methadone. Pain Med 9(3):315–344PubMedCrossRef
46.
Zurück zum Zitat Cascorbi I (2003) Pharmacogenetics of cytochrome p4502d6: genetic background and clinical implication. Eur J Clin Investig 33(Suppl 2):17–22CrossRef Cascorbi I (2003) Pharmacogenetics of cytochrome p4502d6: genetic background and clinical implication. Eur J Clin Investig 33(Suppl 2):17–22CrossRef
47.
Zurück zum Zitat Gardiner SJ, Begg EJ (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58(3):521–590PubMedCrossRef Gardiner SJ, Begg EJ (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58(3):521–590PubMedCrossRef
48.
Zurück zum Zitat Kollek R, van Aken J, Feuerstein G, Schmedders M (2006) Pharmacogenetics, adverse drug reactions and public health. Community Genet 9(1):50–54PubMedCrossRef Kollek R, van Aken J, Feuerstein G, Schmedders M (2006) Pharmacogenetics, adverse drug reactions and public health. Community Genet 9(1):50–54PubMedCrossRef
49.
Zurück zum Zitat Stipp D (2000) A DNA tragedy. Fortune 142(10):170–174, 178, 180 passimPubMed Stipp D (2000) A DNA tragedy. Fortune 142(10):170–174, 178, 180 passimPubMed
50.
Zurück zum Zitat Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F (2007) Concentrations of tramadol and o-desmethyltramadol enantiomers in different cyp2d6 genotypes. Clin Pharmacol Ther 82(1):41–47PubMedCrossRef Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F (2007) Concentrations of tramadol and o-desmethyltramadol enantiomers in different cyp2d6 genotypes. Clin Pharmacol Ther 82(1):41–47PubMedCrossRef
51.
Zurück zum Zitat Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J (2004) Codeine intoxication associated with ultrarapid cyp2d6 metabolism. N Engl J Med 351(27):2827–2831PubMedCrossRef Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J (2004) Codeine intoxication associated with ultrarapid cyp2d6 metabolism. N Engl J Med 351(27):2827–2831PubMedCrossRef
52.
Zurück zum Zitat Koski A (2005) Interpretation of postmortem toxicology results: pharmacogenetics and drug–alcohol interaction. PhD thesis, University of Helsinki, Helsinki, Finland Koski A (2005) Interpretation of postmortem toxicology results: pharmacogenetics and drug–alcohol interaction. PhD thesis, University of Helsinki, Helsinki, Finland
53.
Zurück zum Zitat Skopp G (2004) Preanalytic aspects in postmortem toxicology. Forensic Sci Int 142(2–3):75–100PubMedCrossRef Skopp G (2004) Preanalytic aspects in postmortem toxicology. Forensic Sci Int 142(2–3):75–100PubMedCrossRef
54.
Zurück zum Zitat Levisky JA, Bowerman DL, Jenkins WW, Johnson DG, Karch SB (2001) Drugs in postmortem adipose tissues: evidence of antemortem deposition. Forensic Sci Int 121(3):157–160PubMedCrossRef Levisky JA, Bowerman DL, Jenkins WW, Johnson DG, Karch SB (2001) Drugs in postmortem adipose tissues: evidence of antemortem deposition. Forensic Sci Int 121(3):157–160PubMedCrossRef
55.
56.
Zurück zum Zitat Wagner M (2003) Stability of drugs of abuse in biological specimens. MSc thesis, Columbia Pacific University Wagner M (2003) Stability of drugs of abuse in biological specimens. MSc thesis, Columbia Pacific University
57.
Zurück zum Zitat Sporer KA (1995) The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf 13(2):94–104PubMedCrossRef Sporer KA (1995) The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf 13(2):94–104PubMedCrossRef
58.
Zurück zum Zitat Gillman PK (2007) Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 151(6):737–748PubMedCrossRef Gillman PK (2007) Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 151(6):737–748PubMedCrossRef
59.
Zurück zum Zitat Gillman PK (1999) The serotonin syndrome and its treatment. J Psychopharmacol 13(1):100–109PubMedCrossRef Gillman PK (1999) The serotonin syndrome and its treatment. J Psychopharmacol 13(1):100–109PubMedCrossRef
60.
Zurück zum Zitat Fisher AA, Davis MW (2002) Serotonin syndrome caused by selective serotonin reuptake-inhibitors–metoclopramide interaction. Ann Pharmacother 36(1):67–71PubMedCrossRef Fisher AA, Davis MW (2002) Serotonin syndrome caused by selective serotonin reuptake-inhibitors–metoclopramide interaction. Ann Pharmacother 36(1):67–71PubMedCrossRef
61.
Zurück zum Zitat Bush E, Miller C, Friedman I (2006) A case of serotonin syndrome and mutism associated with methadone. J Palliat Med 9(6):1257–1259PubMedCrossRef Bush E, Miller C, Friedman I (2006) A case of serotonin syndrome and mutism associated with methadone. J Palliat Med 9(6):1257–1259PubMedCrossRef
Metadaten
Titel
Deaths involving contraindicated and inappropriate combinations of serotonergic drugs
verfasst von
Jennifer L. Pilgrim
Dimitri Gerostamoulos
Olaf H. Drummer
Publikationsdatum
01.11.2011
Verlag
Springer-Verlag
Erschienen in
International Journal of Legal Medicine / Ausgabe 6/2011
Print ISSN: 0937-9827
Elektronische ISSN: 1437-1596
DOI
https://doi.org/10.1007/s00414-010-0536-3

Weitere Artikel der Ausgabe 6/2011

International Journal of Legal Medicine 6/2011 Zur Ausgabe

Neu im Fachgebiet Rechtsmedizin

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …